1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Neoantigen Targeted Therapies Market, by Target Disease Indication
6.1. Introduction
6.2. Bone Cancer
6.3. Colorectal Cancer
6.4. Gynecological Cancer
6.5. Non-small Cell Lung Cancer
6.6. Renal Cell Carcinoma

7. Neoantigen Targeted Therapies Market, by Neoantigens Type
7.1. Introduction
7.2. Off-the-shelf Neoantigens
7.3. Personalized Neoantigens

8. Neoantigen Targeted Therapies Market, by Immunotherapy Type
8.1. Introduction
8.2. DNA / RNA-based Vaccines
8.3. Dendritic Cell Vaccines
8.4. Protein / Peptide-based Vaccines
8.5. TIL-based Therapies

9. Neoantigen Targeted Therapies Market, by Route of Administration
9.1. Introduction
9.2. Intradermal
9.3. Intravenous
9.4. Subcutaneous

10. California Neoantigen Targeted Therapies Market

11. Florida Neoantigen Targeted Therapies Market

12. Illinois Neoantigen Targeted Therapies Market

13. New York Neoantigen Targeted Therapies Market

14. Ohio Neoantigen Targeted Therapies Market

15. Pennsylvania Neoantigen Targeted Therapies Market

16. Texas Neoantigen Targeted Therapies Market

17. Competitive Landscape
17.1. FPNV Positioning Matrix
17.1.1. Quadrants
17.1.2. Business Strategy
17.1.3. Product Satisfaction
17.2. Market Ranking Analysis
17.3. Market Share Analysis, By Key Player
17.4. Competitive Scenario
17.4.1. Merger & Acquisition
17.4.2. Agreement, Collaboration, & Partnership
17.4.3. New Product Launch & Enhancement
17.4.4. Investment & Funding
17.4.5. Award, Recognition, & Expansion

18. Company Usability Profiles
18.1. Aduro Biotech, Inc.
18.2. Bavarian Nordic
18.3. Caladrius Biosciences
18.4. Genocea Biosciences
18.5. Gradalis
18.6. Immunicum
18.7. Immunovative Therapies
18.8. Iovance Biotherapeutics
18.9. Medigene
18.10. Neon Therapeutics
18.11. Precision Biologics
18.12. Vaxon Biotech

19. Appendix
19.1. Discussion Guide
19.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: MARKET DYNAMICS
FIGURE 3. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2020 VS 2027 (%)
FIGURE 4. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2020 VS 2027 (USD MILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2027
FIGURE 6. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, 2018-2027 (USD MILLION)
FIGURE 7. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 8. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, 2018-2027 (USD MILLION)
FIGURE 9. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, 2018-2027 (USD MILLION)
FIGURE 11. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 12. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2027 (USD MILLION)
FIGURE 13. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 14. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2027 (USD MILLION)
FIGURE 15. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 16. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2020 VS 2027 (%)
FIGURE 17. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2020 VS 2027 (USD MILLION)
FIGURE 18. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2027
FIGURE 19. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY OFF-THE-SHELF NEOANTIGENS, 2018-2027 (USD MILLION)
FIGURE 20. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY OFF-THE-SHELF NEOANTIGENS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 21. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2027 (USD MILLION)
FIGURE 22. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 23. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2020 VS 2027 (%)
FIGURE 24. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2020 VS 2027 (USD MILLION)
FIGURE 25. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2027
FIGURE 26. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA / RNA-BASED VACCINES, 2018-2027 (USD MILLION)
FIGURE 27. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA / RNA-BASED VACCINES, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 28. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL VACCINES, 2018-2027 (USD MILLION)
FIGURE 29. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 30. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PROTEIN / PEPTIDE-BASED VACCINES, 2018-2027 (USD MILLION)
FIGURE 31. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PROTEIN / PEPTIDE-BASED VACCINES, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 32. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TIL-BASED THERAPIES, 2018-2027 (USD MILLION)
FIGURE 33. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TIL-BASED THERAPIES, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 34. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2027 (%)
FIGURE 35. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2027 (USD MILLION)
FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2027
FIGURE 37. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRADERMAL, 2018-2027 (USD MILLION)
FIGURE 38. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRADERMAL, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 39. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, 2018-2027 (USD MILLION)
FIGURE 40. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 41. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, 2018-2027 (USD MILLION)
FIGURE 42. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 43. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: FPNV POSITIONING MATRIX
FIGURE 44. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 45. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET, BY TYPE

List of Tables

TABLE 1. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY STATE, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY STATE, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY OFF-THE-SHELF NEOANTIGENS, BY STATE, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2027 (USD MILLION)
TABLE 13. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA / RNA-BASED VACCINES, BY STATE, 2018-2027 (USD MILLION)
TABLE 14. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY STATE, 2018-2027 (USD MILLION)
TABLE 15. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PROTEIN / PEPTIDE-BASED VACCINES, BY STATE, 2018-2027 (USD MILLION)
TABLE 16. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TIL-BASED THERAPIES, BY STATE, 2018-2027 (USD MILLION)
TABLE 17. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 18. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRADERMAL, BY STATE, 2018-2027 (USD MILLION)
TABLE 19. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY STATE, 2018-2027 (USD MILLION)
TABLE 20. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY STATE, 2018-2027 (USD MILLION)
TABLE 21. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: SCORES
TABLE 22. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: BUSINESS STRATEGY
TABLE 23. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: PRODUCT SATISFACTION
TABLE 24. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: RANKING
TABLE 25. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 26. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: MERGER & ACQUISITION
TABLE 27. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 28. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 29. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: INVESTMENT & FUNDING
TABLE 30. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 31. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET: LICENSE & PRICING

Companies Mentioned

Aduro Biotech, Inc.
Bavarian Nordic
Caladrius Biosciences
Genocea Biosciences
Gradalis
Immunicum
Immunovative Therapies
Iovance Biotherapeutics
Medigene
Neon Therapeutics
Precision Biologics
Vaxon Biotech